Pharmacogenetics of β2-Agonists

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis

Background: Chronic obstructive pulmonary disease (COPD) is usually considered one of the leading causes of death worldwide, so finding proper therapeutic strategies for this disease is of high importance. In this meta-analysis, we reviewed the existing literature on the efficacy and safety of conventional long acting beta agonists (LABAs) in COPD patients. Methods: We searched MEDLINE and G...

Safety of β2-agonists: a 50-year debate closed?

Affiliations: University Hospital, Hôpital Arnaud de Villeneuve, Dept of Respiratory Diseases, Montpellier, Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Respiratory and Environmental Epidemiology team, Villejuif, Inserm U1046, Montpellier University 1 and 2, Montpellier, and Allergy Division, Pneumology Dept, INSERM U657, Hôpital Arnaud de Villeneuve, Universit...

Safety of long-acting β2-agonists in asthma.

Inhaled β2-agonists in asthma management: an evolving story

The history and the future of inhaled β2-agonists in asthma management http://ow.ly/s1s4305l4k4.

β2-Adrenergic agonists attenuate organic dust-induced lung inflammation.

Agricultural dust exposure results in significant lung inflammation, and individuals working in concentrated animal feeding operations (CAFOs) are at risk for chronic airway inflammatory diseases. Exposure of bronchial epithelial cells to aqueous extracts of hog CAFO dusts (HDE) leads to inflammatory cytokine production that is driven by protein kinase C (PKC) activation. cAMP-dependent protein...